Merry Christmas for whom?
Definitely for Big Pharma. Developed countries are pursuing a third or even a fourth shot due to Omicron and companies prioritize them because they pay higher prices than low-income countries can ever afford.
According to a World Health Organization study, this could mean a 3 billion dose shortage for low-income countries in 2022, widening the vaccination gap. This is not just a crisis of supply, it’s a crisis of ethics. How come there are countries that have vaccinated less than 1% of their population while others guarantee record-high revenues and even a 4th dose?
The scenario developed countries are trying to avoid at all costs—a new round of lockdowns, the rise in infection rates and an overwhelmed healthcare system—developing countries are living non-stop since the beginning of the pandemic in 2020.
Scientists across the globe agree that ultimately this asymmetry in vaccination rates means new variants are bound to emerge. Some even point out that sooner or later a variant capable of evading current vaccines may arise. This nightmarish scenario is music to the ears of the corporate monopoly in control of vaccine development, supply and distribution: a new variant is great for business.
#Fem4PeoplesVaccine
